PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29186917-5	2017	Lazabemide is a monoamine oxidase (MAO)-B inhibitor, a class of compounds that slows the depletion of dopamine stores in Parkinson"s disease and elevates dopamine levels produced by exogenously administered l-dopa.	Levodopa	207-213	monoamine oxidase B	Mus musculus	16-41	
11980384-13	2002	), a MAO-B inhibitor potentiated the motor stimulant actions of subthreshold doses of the L-DOPA (100 mg/kg i.p.)	Levodopa	90-96	monoamine oxidase B	Mus musculus	5-10	
11980384-19	2002	It is concluded that COMT and MAO-B enzymes play an important role in the metabolism of dopamine and administration of a COMT or MAO-B inhibitor may prove to be a better adjunct to L-DOPA therapy than a dopamine receptor agonist in Parkinson"s disease.	Levodopa	181-187	monoamine oxidase B	Mus musculus	129-134	
18286173-2	2008	The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert with the dopamine precursor L-DOPA.	Levodopa	140-146	monoamine oxidase B	Mus musculus	4-9	
31584763-1	2019	Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy.	Levodopa	92-100	monoamine oxidase B	Mus musculus	0-19